The Polycystic Ovarian Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polycystic Ovarian Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Polycystic Ovarian Syndrome by 16 companies/universities/institutes. The top development phase for Polycystic Ovarian Syndrome is preclinical with six drugs in that stage. The Polycystic Ovarian Syndrome pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Polycystic Ovarian Syndrome pipeline products market are: Massachusetts General Hospital, Tel Aviv University and Zydus Lifesciences.
The key targets in the Polycystic Ovarian Syndrome pipeline products market include Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR), Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31), and Corticotropin Releasing Factor Receptor 1 (Corticotropin Releasing Hormone Receptor 1 or CRHR1).
The key mechanisms of action in the Polycystic Ovarian Syndrome pipeline product include Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase (NADPH)] Kinase or AMPK or EC 2.7.11.31) Activator with two drugs in Phase I. The Polycystic Ovarian Syndrome pipeline products include six routes of administration with the top ROA being Oral and six key molecule types in the Polycystic Ovarian Syndrome pipeline products market including Small Molecule, and Recombinant Protein.
Polycystic Ovarian Syndrome overview
Polycystic ovarian syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen, and polycystic ovaries. The main risk factor for PCOS is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.
For a complete picture of Polycystic Ovarian Syndrome’s pipeline drug market, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
